Mutations in multiple domains of gag drive the emergence of in vitro resistance to the phosphonate-containing HIV-1 protease inhibitor GS-8374

Journal of Virology

Volumn 87, Issue 1, 2013, Pages 454-463

  Stray, Kirsten M ^a   Callebaut, Christian ^a   Glass, Bärbel ^b   Tsai, Luong ^a   Xu, Lianhong ^a   Müller, Barbara ^b   Kräusslich, Hans Georg ^b   Cihlar, Tomas ^a  

^a GILEAD SCIENCES   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3,3A,6A HEXAHYDROFURO[2,3 B]FURAN 3 YL 1 [4 [(DIETHOXYPHOSPHORYL)METHOXY]PHENYL] 3 HYDROXY 4 (N ISOBUTYL 4 METHOXYPHENYLSULFONAMIDO)BUTAN 2 YLCARBAMATE; AMPRENAVIR; ATAZANAVIR; DARUNAVIR; GAG PROTEIN; GS 8374; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR; POL PROTEIN; PROTEINASE; SAQUINAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; ENZYME ACTIVE SITE; GENETIC VARIABILITY; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO SELECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; VIRUS CAPSID; VIRUS ISOLATION; VIRUS MUTATION; VIRUS NUCLEOCAPSID; VIRUS REPLICATION;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION, MISSENSE; SELECTION, GENETIC; SERIAL PASSAGE;

HUMAN IMMUNODEFICIENCY VIRUS 1; MIRIDAE;

EID: 84871971997     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01211-12     Document Type: Article

References (40)

1. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, Schrager LK, Phair JP. 1998. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 280:1497-1503.
2. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ. 2001. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann. Intern. Med. 135:17-26.
3. Palella FJ, Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
4. Fernandez-Montero JV, Barreiro P, Soriano V. 2009. HIV protease inhibitors: recent clinical trials and recommendations on use. Expert Opin. Pharmacother 10:1615-1629.
5. Wensing AM, van Maarseveen NM, Nijhuis M. 2010. Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antivir. Res. 85:59-74.
6. Zolopa AR. 2010. The evolution of HIV treatment guidelines: current state-of-the-art of ART. Antivir. Res. 85:241-244.
7. Naggie S, Hicks C. 2010. Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options. J. Antimicrob. Chemother. 65:1094-1099.
8. Pillay D, Green H, Matthias R, Dunn D, Phillips A, Sabin C, Evans B. 2005. Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J. Infect. Dis. 192:967-973.
9. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF, Bozzette SA. 2004. The prevalence of antiretroviral drug resistance in the United States. AIDS (London) 18:1393-1401.
10. Tamalet C, Fantini J, Tourres C, Yahi N. 2003. Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7,000 genotypes. AIDS (London) 17:2383-2388.
11. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347:385-394.
12. Wensing AMJ, van de Vijver DAMC, Asjo B, Balotta C, Camacho R, de Luca A, de Mendoza C, Deroo S, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hoepelman A, Horban A, Korn K, Kuecherer C, Leitner T, Nielsen C, Ormaasen V, Perrin L, Paraskevis D, Puchhammer E, Roman F, Ruiz L, Salminen M, Schmit JCC, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Yerly S, Zazzi M, Boucher CAB, Programme SPREAD. 2003. Analysis from more than 1600 newly diagnosed patients with HIV from 17 European countries shows that 10% of the patients carry primary drug resistance: the CATCHStudy. Abstr LB01. Second International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, France.
13. Taiwo B. 2009. Understanding transmitted HIV resistance through the experience in the U. S. A. Int. J. Infect. Dis. 13:552-559.
14. Yusa K, Harada S. 2004. Acquisition of multi-PI (protease inhibitor) resistance in HIV-1 in vivo and in vitro. Curr. Pharm. Des. 10:4055-4064.
15. Shafer RW, Schapiro JM. 2008. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev. 10: 67-84.
16. Callebaut C, Stray K, Tsai L, Williams M, Yang ZY, Cannizzaro C, Leavitt SA, Liu X, Wang K, Murray BP, Mulato A, Hatada M, Priskich T, Parkin N, Swaminathan S, Lee W, He GX, Xu L, Cihlar T. 2011. In vitro characterization of GS-8374, a novel phosphonate-containing inhibitor of HIV-1 protease with a favorable resistance profile. Antimicrob. Agents Chemother. 55:1366-1376.
17. Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, Schipper P, Gulnik S, Boucher CA. 1999. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13:2349-2359.
18. van Maarseveen NM, Wensing AM, de Jong D, Taconis M, Borleffs JC, Boucher CA, Nijhuis M. 2007. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation. J. Infect. Dis. 195: 399-409.
19. Holguin A, Paxinos E, Hertogs K, Womac C, Soriano V. 2004. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J. Clin. Virol. 31:215-220.
20. Kantor R, Katzenstein D. 2003. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev. 5:25-35.
21. Dauber DS, Ziermann R, Parkin N, Maly DJ, Mahrus S, Harris JL, Ellman JA, Petropoulos C, Craik CS. 2002. Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease. J. Virol. 76:1359-1368.
22. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70:3763-3769.
23. Maguire MF, Guinea R, Griffin P, Macmanus S, Elston RC, Wolfram J, Richards N, Hanlon MH, Porter DJ, Wrin T, Parkin N, Tisdale M, Furfine E, Petropoulos C, Snowden BW, Kleim JP. 2002. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J. Virol. 76:7398-7406.
24. Prabu-Jeyabalan M, Nalivaika EA, King NM, Schiffer CA. 2004. Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J. Virol. 78:12446-12454.
25. Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, Glass B, Rovenska M, de Jong D, Chappey C, Goedegebuure IW, Heilek-Snyder G, Dulude D, Cammack N, Brakier-Gingras L, Konvalinka J, Parkin N, Krausslich HG, Brun-Vezinet F, Boucher CA. 2007. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med. 4:e36. doi:10.1371/journal.pmed.0040036.
26. Dam E, Quercia R, Glass B, Descamps D, Launay O, Duval X, Krausslich HG, Hance AJ, Clavel F. 2009. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog. 5:e1000345. doi:10.1371/journal.ppat.1000345.
27. Cihlar T, He GX, Liu X, Chen JM, Hatada M, Swaminathan S, McDermott MJ, Yang ZY, Mulato AS, Chen X, Leavitt SA, Stray KM, Lee WA. 2006. Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring. J. Mol. Biol. 363:635-647.
28. He GX, Yang ZY, Williams M, Callebaut C, Cihlar T, Murray BP, Yang C, Mitchell ML, Liu HT, Wang JY, Arimilli M, Eisenberg E, Stray KM, Tsai LK, Hatada M, Chen XW, Chen JM, Wang YJ, Lee MS, Strickley RG, Iwata Q, Zheng XB, Kim CU, Swaminathan S, Desai MC, Lee WA, Xu LH. 2011. Discovery of GS-8374, a potent human immunodeficiency virus type 1 protease inhibitor with a superior resistance profile. Med-ChemComm 2:1093-1098.
29. Gong YF, Robinson BS, Rose RE, Deminie C, Spicer TP, Stock D, Colonno RJ, Lin PF. 2000. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob. Agents Chemother. 44:2319-2326.
30. Weinheimer S, Discotto L, Friborg J, Yang H, Colonno R. 2005. Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones. Antimicrob. Agents Chemother. 49:3816-3824.
31. Kempf DJ, Isaacson JD, King MS, Brun SC, Xu Y, Real K, Bernstein BM, Japour AJ, Sun E, Rode RA. 2001. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J. Virol. 75:7462-7469.
32. Grossman Z, Vardinon N, Chemtob D, Alkan ML, Bentwich Z, Burke M, Gottesman G, Istomin V, Levi I, Maayan S, Shahar E, Schapiro JM. 2001. Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B. AIDS 15:1453-1460.
33. Manosuthi W, Butler DM, Perez-Santiago J, Poon AF, Pillai SK, Mehta SR, Pacold ME, Richman DD, Pond SK, Smith DM. 2010. Protease polymorphisms in HIV-1 subtype CRF01_AE represent selection by antiretroviral therapy and host immune pressure. AIDS (London) 24:411-416.
34. Rhee SY, Taylor J, Wadhera G, Ben-Hur A, Brutlag DL, Shafer RW. 2006. Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc. Natl. Acad. Sci. U. S. A. 103:17355-17360.
35. Parkin NT, Chamorro M, Varmus HE. 1992. Human immunodeficiency virus type 1 gag-pol frameshifting is dependent on downstream mRNA secondary structure: demonstration by expression in vivo. J. Virol. 66: 5147-5151.
36. Louis JM, Dyda F, Nashed NT, Kimmel AR, Davies DR. 1998. Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease. Biochemistry 37:2105-2110.
37. Larrouy L, Chazallon C, Landman R, Capitant C, Peytavin G, Collin G, Charpentier C, Storto A, Pialoux G, Katlama C, Girard PM, Yeni P, Aboulker JP, Brun-Vezinet F, Descamps D. 2010. Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naive HIV-infected patients. Antimicrob. Agents Chemother. 54:2910-2919.
38. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. 2007. Update of the drug resistance mutations in HIV-1: 2007. Top. HIV Med. 15:119-125.
39. Parry CM, Kolli M, Myers RE, Cane PA, Schiffer C, Pillay D. 2011. Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity. Antimicrob. Agents Chemother. 55:1106-1113.
40. Gatanaga H, Das D, Suzuki Y, Yeh DD, Hussain KA, Ghosh AK, Mitsuya H. 2006. Altered HIV-1 Gag protein interactions with cyclophilin A (CypA) on the acquisition of H219Q and H219P substitutions in the CypA binding loop. J. Biol. Chem. 281:1241-1250.